You are using an outdated browser. Please upgrade your browser to improve your experience.

Tchem
UBE2D3
Ubiquitin-conjugating enzyme E2 D3

Protein Summary
Description
Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-, as well as 'Lys-48'-linked polyubiquitination. Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin. Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA. Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase. Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following i ...more
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000321805
  • ENSP00000318494
  • ENSG00000109332
  • ENST00000338145
  • ENSP00000337208
  • ENST00000343106
  • ENSP00000345285
  • ENST00000349311
  • ENSP00000344069
  • ENST00000357194
  • ENSP00000349722
  • ENST00000394801
  • ENSP00000378280
  • ENST00000394803
  • ENSP00000378282
  • ENST00000394804
  • ENSP00000378283
  • ENST00000453744
  • ENSP00000396901

Symbol
  • UBC5C
  • UBCH5C
  • UBC4/5
  • UBCH5C
  • E2(17)KB3
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
disease perturbation
1
virus perturbation
1
transcription factor perturbation
0.98
kinase perturbation
0.95
biological process
0.93


Protein Classes
IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 45.79   (req: < 5)
Gene RIFs: 18   (req: <= 3)
Antibodies: 202   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 45.79   (req: >= 5)
Gene RIFs: 18   (req: > 3)
Antibodies: 202   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 19
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 2
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0